[THE ANTIOXIDANT EFFECT OF DALARGIN IN PATIENTS WITH CORONARY HEART DISEASE AND METABOLIC SYNDROME]

Area of Science:

• Cardiology
• Biochemistry
• Pharmacology

Background:

• Coronary heart disease (CHD) and metabolic syndrome (MS) are associated with increased oxidative stress.
• Lipid peroxidation (LPO) and an imbalanced antioxidant system are key factors in cardiovascular disease progression.

Purpose of the Study:

• To investigate the impact of dalargin on lipid peroxidation and the antioxidant system in patients with CHD and MS.
• To compare the effects of standard therapy (ST) versus ST plus dalargin (ST + D) on oxidative stress markers.

Main Methods:

• A study involving 123 patients with stable CHD and MS.
• Comparison of blood redox potential (EP), total antioxidant activity (TAA), oxidized low-density lipoproteins (LDL), and superoxide dismutase (SOD) activity.
• Patients received either ST or ST + D (1 mg intranasally twice daily for 10 days, repeated for 3 months).

Main Results:

• Standard therapy alone did not yield significant changes in EP, oxidized LDL, or SOD activity over 3 months.
• The addition of dalargin (ST + D) significantly decreased oxidative stress markers: blood EP by 10.5% and oxidized LDL by 14% (p < 0.001).
• Dalargin significantly enhanced antioxidant properties: SOD activity increased by 36.1% and TAA by 25.3% (p < 0.001).

Conclusions:

• Dalargin demonstrates a significant therapeutic effect in mitigating oxidative stress in patients with CHD and MS.
• Supplementing standard therapy with dalargin effectively improves the antioxidant system, offering a potential new treatment avenue.